Patient groups rebuke CVS on ICER, saying cost-effectiveness reviews discriminate

14th September 2018 Uncategorised 0

Patient groups are asking CVS to reconsider its move to allow clients to exclude drugs based on guidance from drug cost watchdog ICER, calling cost-effectiveness reviews discriminatory.

More: Patient groups rebuke CVS on ICER, saying cost-effectiveness reviews discriminate
Source: fierce